Plus500 does not provide its products and services to residents of United States.

Plus500 does not provide its products and services to residents of United States.

72% of retail CFD accounts lose money.

Menu

Will the FDA Approve Pfizer’s COVID Vaccine for Ages 12-15?

Plus500 | Tuesday 04 May 2021

The Pfizer COVID-19 vaccine could soon receive FDA approval for use in children between the ages of 12 and 15. The shot may be authorised by early next week in hopes that widespread adoption will ease the start of the school year in September. The news comes a month after the vaccine, which has already been approved for youth above the age of 16, was shown to also provide protection for the younger age groups. Stock prices for Pfizer (PFE) were up by nearly 3% on Monday.

vaccine

A federal official confirmed the expected timeline for approval and also noted that younger children may be in line to receive the vaccinations by the fall. The approval process still requires a recommendation from a federal vaccine advisory committee and the recommendation’s adoption by the CDC. However, both of these steps can be accomplished within a matter of days.

Moderna (MRNA) is also working towards having age restrictions on its COVID-19 vaccine lowered. Testing is currently being conducted on children between the ages of 12 and 17 and results are expected to be released by the summer. In a sign that things are likely going well, the FDA has already given both Pfizer and Moderna authorisation to start trials on children below the age of twelve.

Pfizer and Moderna to Release Q1 Earnings This Week

Pfizer is scheduled to release its Q1 earnings later today and analysts will be looking for the strength of the company’s COVID-19 vaccine revenue. This could possibly grow as Pfizer begins to export the vaccine from its U.S. based facilities, first to Mexico and Canada, and eventually to other countries around the world. Until recently, the Biden administration had relied upon wartime powers to prioritise vaccine sales for the U.S. government. However, the U.S. was criticised for withholding much-needed supplies from countries that could not afford to produce their own vaccines. Now that 40% of American adults are fully vaccinated, President Biden has pledged to send additional vaccines overseas.

Moderna is also expected to rely heavily on its COVID vaccine to bump up its Q1 earnings, which are scheduled to come out on May 6th. The company sold 88 million doses of the vaccine in the U.S. alone, along with millions more worldwide. Still, these earnings must be balanced against the costs of running pediatric and adolescent trials, as well as new studies on different COVID vaccine variants. The company also expects to see profits from its partnerships with AstraZeneca (AZN-L) and Merck (MRK.DE), who use Moderna’s mRNA technology to develop different therapies.

While the FDA is considering the Pfizer and Moderna vaccines for use in younger populations of children, it remains to be seen what kind of impact this will have on the stock prices of these companies in the future.


Get more from Plus500

Expand Your Knowledge

Videos & Articles help you expand your trading knowledge.

Prepare Your Trades

Our Economic calendar helps you explore global market events.

Trade Without Surprises

Understand the full costs of your trades now for better expense management later.


This information is written by Plus500 Ltd. The information is provided for general purposes only, and does not take into account any personal circumstances or objectives. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, if necessary, seek professional advice. No representation or warranty is given as to the accuracy or completeness of this information. It does not constitute financial, investment or other advice on which you can rely. Any references to past performance, historical returns, future projections, and statistical forecasts are no guarantee of future returns or future performance. Plus500 will not be held responsible for any use that may be made of this information and for any consequences that may result from such use. Hence, any person acting based on this information does so at their own discretion. The information has not been prepared in accordance with legal requirements designed to promote the independence of investment research.

Cryptocurrency CFDs are not available to Retail Clients.

Need Help?
24/7 Support